{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:42:43Z","timestamp":1779309763786,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00011-020-01366-6","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T09:02:58Z","timestamp":1590656578000},"page":"757-763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-3191","authenticated-orcid":false,"given":"Salvatore","family":"Bellinvia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Schisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Banfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fallico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Murabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"1366_CR1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523\u201334.","journal-title":"Nat Rev Microbiol"},{"key":"1366_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u20133. https:\/\/doi.org\/10.1038\/s41586-020-2012-7.","journal-title":"Nature"},{"key":"1366_CR3","unstructured":"World Health Organization. Coronavirus disease (COVID-19) outbreak. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. Accessed Feb 2020"},{"issue":"13","key":"1366_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa2001316.","journal-title":"N Engl J Med"},{"issue":"10223","key":"1366_CR5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet"},{"issue":"10223","key":"1366_CR6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313.","journal-title":"Lancet"},{"issue":"8","key":"1366_CR7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fpubh.2020.00152","volume":"29","author":"JM Jin","year":"2020","unstructured":"Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;29(8):152.","journal-title":"Front Public Health"},{"issue":"2","key":"1366_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","volume":"10","author":"X Li","year":"2020","unstructured":"Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102\u20138. https:\/\/doi.org\/10.1016\/j.jpha.2020.03.001.","journal-title":"J Pharm Anal"},{"issue":"1","key":"1366_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12932\/AP-200220-0772","volume":"38","author":"E Prompetchara","year":"2020","unstructured":"Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1\u20139. https:\/\/doi.org\/10.12932\/AP-200220-0772.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1","key":"1366_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.12932\/AP-200220-0773","volume":"38","author":"B Shanmugaraj","year":"2020","unstructured":"Shanmugaraj B, Siriwattananon K, Wangkanont K, et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10\u20138. https:\/\/doi.org\/10.12932\/AP-200220-0773.","journal-title":"Asian Pac J Allergy Immunol."},{"issue":"5","key":"1366_CR11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","volume":"92","author":"L Zhang","year":"2020","unstructured":"Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92(5):479\u201390.","journal-title":"J Med Virol"},{"issue":"4","key":"1366_CR12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","volume":"92","author":"G Li","year":"2020","unstructured":"Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424\u201332.","journal-title":"J Med Virol"},{"issue":"4","key":"1366_CR13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586\u201390.","journal-title":"Intensive Care Med"},{"issue":"2","key":"1366_CR14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631\u20137.","journal-title":"J Pathol"},{"issue":"4","key":"1366_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40560-016-0147-2","volume":"23","author":"N Matsuda","year":"2016","unstructured":"Matsuda N. Alert cell strategy in SIRS-induced vasculitis: sepsis and endothelial cells. J Intensive Care. 2016;23(4):21.","journal-title":"J Intensive Care"},{"issue":"9","key":"1366_CR16","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1128\/IAI.71.9.4873-4882.2003","volume":"71","author":"Q Li","year":"2003","unstructured":"Li Q, Cherayil BJ. Role of toll-like receptor 4 in macrophage activation and tolerance during salmonella enterica serovar typhimurium infection. Infect Immun. 2003;71(9):4873\u201382.","journal-title":"Infect Immun"},{"issue":"1","key":"1366_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intimm\/dxh186","volume":"17","author":"K Takeda","year":"2005","unstructured":"Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1\u201314.","journal-title":"Int Immunol"},{"issue":"3","key":"1366_CR18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1473-3099(05)01308-3","volume":"5","author":"NW Schr\u00f6der","year":"2005","unstructured":"Schr\u00f6der NW, Schumann RR. Single nucleotide polymorphisms of toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005;5(3):156\u201364.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1366_CR19","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.4049\/jimmunol.181.8.5490","volume":"181","author":"CK Li","year":"2008","unstructured":"Li CK, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181(8):5490\u2013500.","journal-title":"J Immunol"},{"issue":"9","key":"1366_CR20","first-page":"e23","volume":"1","author":"HL Janice Oh","year":"2012","unstructured":"Janice Oh HL, Ken-En Gan S, Bertoletti A, et al. Understanding the T cell immune response in SARS coronavirus infection. Emerg Microbes Infect. 2012;1(9):e23.","journal-title":"Emerg Microbes Infect."},{"issue":"10","key":"1366_CR21","doi-asserted-by":"crossref","first-page":"e1000636","DOI":"10.1371\/journal.ppat.1000636","volume":"5","author":"J Zhao","year":"2009","unstructured":"Zhao J, Zhao J, Van Rooijen N, et al. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog. 2009;5(10):e1000636.","journal-title":"PLoS Pathog."},{"key":"1366_CR22","doi-asserted-by":"crossref","first-page":"25359","DOI":"10.1038\/srep25359","volume":"6","author":"CK Min","year":"2016","unstructured":"Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6:25359.","journal-title":"Sci Rep."},{"issue":"4","key":"1366_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420\u20132. https:\/\/doi.org\/10.1016\/S2213-2600(20)30076-X.","journal-title":"Lancet Respir Med."},{"issue":"17","key":"1366_CR24","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1056\/NEJMc2007575","volume":"382","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xiao M, Zhang S, Zhang S, Li Y. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38. https:\/\/doi.org\/10.1056\/NEJMc2007575.","journal-title":"N Engl J Med"},{"issue":"3","key":"1366_CR25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.61.3.195","volume":"61","author":"G Espinosa","year":"2002","unstructured":"Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis. 2002;61(3):195\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1366_CR26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ard.2005.045443","volume":"65","author":"Y Shoenfeld","year":"2006","unstructured":"Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis. 2006;65(1):2\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1366_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14817","author":"N Tang","year":"2019","unstructured":"Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. https:\/\/doi.org\/10.1111\/jth.14817.","journal-title":"J Thromb Haemost"},{"key":"1366_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley F, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0.","journal-title":"Lancet."},{"key":"1366_CR29","unstructured":"Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Feb 13, 2020. https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49409. Accessed 6 Mar 2020."},{"key":"1366_CR30","unstructured":"AIFA e Istituto Nazionale per lo studio e la cura dei tumori di Napoli avviano uno studio per l'utilizzo di Tocilizumab nella malattia COVID 19. https:\/\/www.aifa.gov.it\/web\/guest\/-\/aifa-e-istituto-nazionale-per-lo-studio-e-la-cura-dei-tumeri-di-napoli-avviano-uno-studio-per-l-utilizzo-di-tocilizumab-nella-malattia-covid-19. Accessed Mar 2020"},{"key":"1366_CR31","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30\u201331.","journal-title":"Lancet"},{"key":"1366_CR32","unstructured":"Clinical Trials\u2014COVID-19 (AIFA) https:\/\/www.aifa.gov.it\/sperimentazioni-cliniche-covid-19. Accessed May 2020"},{"key":"1366_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0328-z","author":"O Pacha","year":"2020","unstructured":"Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020. https:\/\/doi.org\/10.1038\/s41577-020-0328-z.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1366_CR34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1017\/S0029665112000092","volume":"71","author":"FP de Heredia","year":"2012","unstructured":"de Heredia FP, G\u00f3mez-Mart\u00ednez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012;71(2):332\u20138.","journal-title":"Proc Nutr Soc"},{"issue":"1","key":"1366_CR35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1590\/0001-3765201720160487","volume":"89","author":"E Fuentes","year":"2017","unstructured":"Fuentes E, Fuentes M, Alarc\u00f3n M, et al. Immune system dysfunction in the elderly. An Acad Bras Cienc. 2017;89(1):285\u201399.","journal-title":"An Acad Bras Cienc."},{"issue":"1","key":"1366_CR36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40635-019-0260-3","volume":"7","author":"A Gillis","year":"2019","unstructured":"Gillis A, Beil M, Halevi-Tobias K, et al. Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics-analysis of a new mathematical model. Intensive Care Med Exp. 2019;7(1):32.","journal-title":"Intensive Care Med Exp"},{"issue":"16","key":"1366_CR37","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa050333","volume":"353","author":"GD Rubenfeld","year":"2005","unstructured":"Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685\u201393.","journal-title":"N Engl J Med"},{"key":"1366_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994","author":"C Wu","year":"2019","unstructured":"Wu C, Chen X, Cai Y, Xia J, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"1366_CR39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00003246-199607000-00010","volume":"24","author":"RC Bone","year":"1996","unstructured":"Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24(7):1125\u20138.","journal-title":"Crit Care Med"},{"issue":"4","key":"1366_CR40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/CCM.0000000000000100","volume":"42","author":"HG Gomez","year":"2014","unstructured":"Gomez HG, Gonzalez SM, Londo\u00f1o JM, et al. Immunological characterization of compensatory anti-inflammatory response syndrome in patients with severe sepsis: a longitudinal study. Crit Care Med. 2014;42(4):771\u201380.","journal-title":"Crit Care Med."},{"issue":"1","key":"1366_CR41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.CCM.0000194535.82812.BA","volume":"34","author":"GS Martin","year":"2006","unstructured":"Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34(1):15\u2013211.","journal-title":"Crit Care Med"},{"key":"1366_CR42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","volume":"105","author":"G Pawelec","year":"2018","unstructured":"Pawelec G. Age and immunity: What is \"immunosenescence\"? Exp Gerontol. 2018;105:4\u20139.","journal-title":"Exp Gerontol"},{"issue":"4","key":"1366_CR43","first-page":"20","volume":"28","author":"S Mart\u00edn","year":"2017","unstructured":"Mart\u00edn S, P\u00e9rez A, Aldecoa C. Sepsis and immunosenescence in the elderly patient: a review. Front Med (Lausanne). 2017;28(4):20.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1366_CR44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/1751143718765407","volume":"19","author":"R Davies","year":"2018","unstructured":"Davies R, O'Dea K, Gordon A. Immune therapy in sepsis: Are we ready to try again? J Intensive Care Soc. 2018;19(4):326\u201344.","journal-title":"J Intensive Care Soc"},{"issue":"26","key":"1366_CR45","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","volume":"334","author":"CJ Fisher Jr","year":"1996","unstructured":"Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996;334(26):1697\u2013702.","journal-title":"N Engl J Med."},{"issue":"2","key":"1366_CR46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/jir.2011.0062","volume":"32","author":"A Kr\u00fcttgen","year":"2012","unstructured":"Kr\u00fcttgen A, Rose-John S. Interleukin-6 in sepsis and capillary leakage syndrome. J Interferon Cytokine Res. 2012;32(2):60\u20135.","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"1366_CR47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10787-019-00628-y","volume":"28","author":"YF Ibrahim","year":"2020","unstructured":"Ibrahim YF, Moussa RA, Bayoumi AMA. Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-\u03baB\/JNK: a possible role of P-glycoprotein. Inflammopharmacology. 2020;28(1):215\u201330.","journal-title":"Inflammopharmacology"},{"issue":"8","key":"1366_CR48","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959\u201370.","journal-title":"Immunotherapy."},{"issue":"2","key":"1366_CR49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326\u201334.","journal-title":"Arthritis Rheumatol"},{"key":"1366_CR50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/TCRM.S155488","volume":"14","author":"S Zhou","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, et al. Biological therapy of traditional therapy-resistant adult-onset Still\u2019s disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167\u201371.","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"1366_CR51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00011-009-0003-0","volume":"58","author":"HP Wu","year":"2009","unstructured":"Wu HP, Chen CK, Chung K, et al. Serial cytokine levels in patients with severe sepsis. Inflamm Res. 2009;58(7):385\u201393.","journal-title":"Inflamm Res"},{"issue":"1","key":"1366_CR52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/viru.26516","volume":"5","author":"JS Boomer","year":"2014","unstructured":"Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence. 2014;5(1):45\u201356.","journal-title":"Virulence"},{"issue":"6","key":"1366_CR53","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/TA.0b013e318256e000","volume":"72","author":"LF Gentile","year":"2012","unstructured":"Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012;72(6):1491\u2013501.","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"1366_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/cyto.b.21043","volume":"84","author":"J Demaret","year":"2013","unstructured":"Demaret J, Walencik A, Jacob MC, et al. Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression in clinical samples. Cytometry B Clin Cytom. Jan-Feb 2013;84(1):59-62. https:\/\/doi.org\/10.1002\/cyto.b.21043 [Epub 14 Sept 2012]","journal-title":"Cytometry B Clin Cytom."},{"issue":"2","key":"1366_CR55","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/cc10112","volume":"15","author":"C Guignant","year":"2011","unstructured":"Guignant C, Lepape A, Huang X, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care. 2011;15(2):R99. https:\/\/doi.org\/10.1186\/cc10112.","journal-title":"Crit Care"},{"issue":"11","key":"1366_CR56","doi-asserted-by":"crossref","first-page":"E2413","DOI":"10.3390\/ijms18112413","volume":"18","author":"NK Patil","year":"2017","unstructured":"Patil NK, Guo Y, Luan L, et al. Targeting immune cell checkpoints during sepsis. Int J Mol Sci. 2017;18(11):E2413.","journal-title":"Int J Mol Sci."},{"issue":"9","key":"1366_CR57","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384\u201391.","journal-title":"J Clin Invest"},{"issue":"6","key":"1366_CR58","doi-asserted-by":"crossref","first-page":"R220","DOI":"10.1186\/cc9354","volume":"14","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Zhou Y, Lou J, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care. 2010;14(6):R220.","journal-title":"Crit Care."},{"issue":"1","key":"1366_CR59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40635-019-0290-x","volume":"8","author":"LM Busch","year":"2020","unstructured":"Busch LM, Sun J, Cui X, et al. Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. Intensive Care Med Exp. 2020;8(1):7.","journal-title":"Intensive Care Med Exp."},{"issue":"11","key":"1366_CR60","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","volume":"123","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904\u201311.","journal-title":"Cancer"},{"issue":"2","key":"1366_CR61","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/cc13787","volume":"18","author":"JM Cavaillon","year":"2014","unstructured":"Cavaillon JM, Eisen D, Annane D. Is boosting the immune system in sepsis appropriate? Crit Care. 2014;18(2):216.","journal-title":"Crit Care"},{"key":"1366_CR62","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2002032.","journal-title":"N Engl J Med."},{"key":"1366_CR63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijid.2017.01.028","volume":"56","author":"M Rao","year":"2017","unstructured":"Rao M, Valentini D, Dodoo E, et al. Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017;56:221\u20138.","journal-title":"Int J Infect Dis"},{"issue":"7109","key":"1366_CR64","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350\u20134.","journal-title":"Nature"},{"issue":"6","key":"1366_CR65","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","volume":"19","author":"B Ye","year":"2015","unstructured":"Ye B, Liu X, Li X, et al. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 2015;19(6):e1694.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1366_CR66","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","volume":"47","author":"L Dyck","year":"2017","unstructured":"Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765\u201379.","journal-title":"Eur J Immunol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-020-01366-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-020-01366-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-020-01366-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:52:04Z","timestamp":1622163124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-020-01366-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1007\/s00011-020-01366-6","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}